Reversal of Bortezomib Resistance in Myelodysplastic Syndrome Cells by MAPK Inhibitors

The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant neoplasms with distinctive clinicopathological features. Currently, there is no specific approach for the treatment of MDS. Here, we report that bortezomib (BTZ), a proteasome inhibitor that has been used to treat plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Yingxing, Wang, Ying, He, Yang, Yang, Shuting, Chen, Zixing, Wang, Yuanyuan, Xing, Shanshan, Shen, Congcong, Amin, Hesham M., Wu, Depei, Song, Yao-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946707/
https://www.ncbi.nlm.nih.gov/pubmed/24608798
http://dx.doi.org/10.1371/journal.pone.0090992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946707/
https://www.ncbi.nlm.nih.gov/pubmed/24608798
http://dx.doi.org/10.1371/journal.pone.0090992

Ejemplares similares